Prelude Therapeutics Incorporated

Equities

PRLD

US74065P1012

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
4.74 USD -0.63% Intraday chart for Prelude Therapeutics Incorporated -1.66% +11.01%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Prelude Therapeutics Incorporated Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:05 PM
JMP Securities Starts Prelude Therapeutics With Market Outperform Rating, $7 Price Target MT
HC Wainwright Downgrades Prelude Therapeutics to Neutral From Buy, Price Target is $5 MT
Prelude Therapeutics Shares Surge Following Shelf Registration MT
Prelude Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Prelude Therapeutics Incorporated - Special Call
Morgan Stanley Downgrades Prelude Therapeutics to Underweight From Equalweight, Cuts Price Target to $4 From $10 MT
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) dropped from NASDAQ Biotechnology Index CI
Prelude Therapeutics Incorporated announced that it has received $24.999997 million in funding CI
Prelude Therapeutics Incorporated announced that it expects to receive $24.999997 million in funding CI
HC Wainwright Trims Prelude Therapeutics' Price Target to $5 From $6, Keeps Buy Rating MT
Prelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
HC Wainwright Adjusts Price Target on Prelude Therapeutics to $6 From $17, Keeps Buy Rating MT
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference CI
Transcript : Prelude Therapeutics Incorporated Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 04:55 PM
Certain Common Stock of Prelude Therapeutics Incorporated are subject to a Lock-Up Agreement Ending on 17-AUG-2023. CI
Certain Restricted Stock Units of Prelude Therapeutics Incorporated are subject to a Lock-Up Agreement Ending on 17-AUG-2023. CI
Certain Stock Options of Prelude Therapeutics Incorporated are subject to a Lock-Up Agreement Ending on 17-AUG-2023. CI
Barclays Adjusts Price Target on Prelude Therapeutics to $5 From $7, Maintains Equalweight Rating MT
Prelude Therapeutics Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Small Cap Comp Value Index CI
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 3000 Index CI
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 3000E Index CI
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Small Cap Completeness Index CI
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 2500 Index CI
Chart Prelude Therapeutics Incorporated
More charts
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
4.74 USD
Average target price
4.75 USD
Spread / Average Target
+0.21%
Consensus